[HTML][HTML] The convalescent sera option for containing COVID-19

A Casadevall, L Pirofski - The Journal of clinical …, 2020 - Am Soc Clin Investig
A Casadevall, L Pirofski
The Journal of clinical investigation, 2020Am Soc Clin Investig
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as
COVID-19. At the time of this writing, SARS-CoV-2 is spreading in multiple countries,
threatening a pandemic that will affect billions of people. This virus appears to be a new
human pathogen. Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs
available for SARS-CoV-2, although many are in rapid development and some may be …
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19. At the time of this writing, SARS-CoV-2 is spreading in multiple countries, threatening a pandemic that will affect billions of people. This virus appears to be a new human pathogen. Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs available for SARS-CoV-2, although many are in rapid development and some may be available in a short time. This Viewpoint argues that human convalescent serum is an option for prevention and treatment of COVID-19 disease that could be rapidly available when there are sufficient numbers of people who have recovered and can donate immunoglobulin-containing serum.
The Journal of Clinical Investigation